Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma, Clear Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × AMG 337 × Clear all
NCT03132155 2024-05-24

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NantPharma, LLC

Phase 2 Terminated
8 enrolled 10 charts
Sarcoma

Sarcoma, Clear Cell

NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Amgen

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡